Publication Name	World Journal of Gastroenterology
Manuscript ID	29937
Country	Italy

Received	2016-08-31 10:54
Peer-Review Started	2016-08-31 21:14
First Decision by Editorial Office Director
Return for Revision	2016-09-23 15:53
Revised	2016-10-01 14:13
Publication Fee Transferred
Second Decision by Editor	2016-12-16 17:22
Second Decision by Editor-in-Chief	2016-12-16 17:29
Final Decision by Editorial Office Director	2016-12-21 16:09
Articles in Press	2016-12-21 16:09
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-12-28 20:24
Publish the Manuscript Online	2017-01-12 13:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Biosimilars in inflammatory bowel disease: A review of post-marketing experience
Manuscript Source	Invited Manuscript
All Author List	Simona Deiana, Tommaso Gabbani and Vito Annese
Funding Agency and Grant Number
Corresponding Author	Vito Annese, MD, Emergency Department, Division of Gastroenterology, AOU Careggi University Hospital, Largo Brambilla 3, 50139 Firenze, Italy. annesev@aou-careggi.toscana.it
Key Words	Adalimumab biosimilar; CTP-13; ZRC-3197; Infliximab biosimilars; Biologic drugs
Core Tip	Some differences between biosimilars and original biologic drugs exist but they are acceptable if they fall within defined “boundaries of tolerance”: variations in some features of the two molecules are considered important only if clinical relevant. Several real-life clinical data are already available in inflammatory bowel disease patients treated with biosimilars with satisfactory outcomes, but further controlled trials are awaited.
Publish Date	2017-01-12 13:49
Citation	Deiana S, Gabbani T, Annese V. Biosimilars in Inflammatory bowel disease: A review of post-marketing experience. World J Gastroenterol 2017; 23(2): 197-203
URL	http://www.wjgnet.com/1007-9327/full/v23/i2/197.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i2.197

Full Article (PDF)	WJG-23-197.pdf
Full Article (Word)	WJG-23-197.doc
Manuscript File	29937-Review.docx
Answering Reviewers	29937-Answering reviewers.pdf
Audio Core Tip	29937-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	29937-Conflict-of-interest statement.pdf
Copyright License Agreement	29937-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	29937-Language certificate.pdf
Peer-review Report	29937-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	29937-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	29937-Scientific misconduct check.pdf
Scientific Editor Work List	29937-Scientific editor work list.pdf